Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 5, 2014, Pages 820-826

  Blanchette, Marie ^a   Tremblay, Luc ^a   Lepage, Martin ^a   Fortin, David ^b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

blood brain barrier; blood brain barrier disruption; blood tumor barrier; dynamic contrast enhanced magnetic resonance imaging; malignant gliomas

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; GADOMER 17;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BLOOD BRAIN BARRIER; BLOOD TUMOR BARRIER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; GLIOMA; HEMISPHERE; MALE; MEMBRANE PERMEABILITY; MOLECULAR SIZE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; GADOLINIUM; GADOLINIUM DTPA; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PERMEABILITY; RATS; RATS, INBRED F344;

EID: 84899973768     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.14     Document Type: Article

References (41)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
3. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998; 42: 1083-1099, discussion 1099-100.
4. Percy DB, Ribot EJ, Chen Y, McFadden C, Simedrea C, Steeg PS et al. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol 2011; 46: 718-725.
5. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010; 16: 5664-5678.
6. Neuwelt EA, Maravilla KR, Frenkel EP, Rapaport SI, Hill SA, Barnett PA. Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest 1979; 64: 684-688.
7. Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH et al. Osmotic bloodbrain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors. Cancer Treat Rep 1981; 65(Suppl 2): 39-43.
8. Ziylan YZ, Robinson PJ, Rapoport SI. Blood-brain barrier permeability to sucrose and dextran after osmotic opening. Am J Physiol 1984; 247: R634-R638.
9. Neuwelt EA, Minna J, Frenkel E, Barnett PA, McCormick CI. Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. Am J Physiol 1986; 250: R875-R883.
10. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005; 103: 2606-2615.
11. Blanchette M, Pellerin M, Tremblay L, Lepage M, Fortin D. Real-time monitoring of gadolinium diethylenetriamine penta-acetic acid during osmotic blood-brain barrier disruption using magnetic resonance imaging in normal Wistar rats. Neurosurgery 2009; 65: 344-350, discussion 350-1.
12. Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000; 88: 637-647.
13. Joshi S, Ergin A, Wang M, Reif R, Zhang J, Bruce JN et al. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol 2010; 104: 11-19.
14. Rapoport SI, Fredericks WR, Ohno K, Pettigrew KD. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am J Physiol 1980; 238: R421-R431.
15. Ohata M, Fredericks WR, Neuwelt EA, Sundaram U, Rapoport SI. [3H]Methotrexate loss from the rat brain following enhanced uptake by osmotic opening of the blood-brain barrier. Cancer Res 1985; 45: 1092-1096.
16. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the bloodbrain and/or blood-tumor barriers. Neurosurgery 1998; 43: 879-886, discussion 886-9.
17. Fortin D, McCormick CI, Remsen LG, Nixon R, Neuwelt EA. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. Neurosurgery 2000; 47: 199-207.
18. Rapoport SI, Robinson PJ. Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann NY Acad Sci 1986; 481: 250-267.
19. Robinson PJ, Rapoport SI. Size selectivity of blood-brain barrier permeability at various times after osmotic opening. Am J Physiol 1987; 253: R459-R466.
20. Nguyen-minh C, Haughton VM, An HS, You JW, Wook S, Ho KC. Contrast media of high and low molecular weights in the detection of recurrent herniated disks. AJNR Am J Neuroradiol 1998; 19: 889-893.
21. Su MY, Wang Z, Nalcioglu O. Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors. J Magn Reson Imaging 1999; 9: 128-137.
22. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 2001; 12: 128-134.
23. Verhoye M, van der Sanden BPJ, PFJW Rijken, Peters HPW, Van der Kogel AJ, Pée G et al. Assessment of the neovascular permeability in glioma xenografts by dynamic T(1) MRI with Gadomer-17. Magn Reson Med 2002; 47: 305-313.
24. Artemov D. Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem 2003; 90: 518-524.
25. Armstrong BK, Smith Q, Rapoport SI, Strohalm J, Kopeček J, Duncan R. Osmotic opening of the blood-brain barrier permeability to N-(2-hydroxypropyl)- methacrylamide copolymers. Effect of polymer -Mw charge and hydrophobicity. J Control Rel 1989; 10: 27-35.
26. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD et al. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 2000; 44: 563-574.
27. Mathieu D, Lecomte R, Tsanaclis AM, Larouche A, Fortin D. Standardization and detailed characterization of the syngeneic Fischer/F98 glioma model. Can J Neurol Sci 2007; 34: 296-306.
28. Blanchette M, Fortin D. Blood-brain barrier disruption in the treatment of brain tumors. Methods Mol Biol 2011; 686: 447-463.
29. Kessler RM, Goble JC, Bird JH, Girton ME, Doppman JL, Rapoport SI et al. Measurement of blood-brain barrier permeability with positron emission tomography and [68Ga]EDTA. J Cereb Blood Flow Metab 1984; 4: 323-328.
30. Neuwelt EA, Barnett PA, Hellström I, Hellström KE, Beaumier P, McCormick CI et al. Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 1988; 48: 4725-4729.
31. Neuwelt EA, Pagel MA, Dix RD. Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier. J Neurosurg 1991; 74: 475-479.
32. Zünkeler B, Carson RE, Olson J, Blasberg RG, Girton M, Bacher J et al. Hyperosmolar blood-brain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82. J Neurosurg 1996; 84: 494-502.
33. Zünkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996; 85: 1056-1065.
34. Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N. Quantification of early blood-brain barrier disruption by in situ brain perfusion technique. Brain Res Brain Res Protoc 2001; 8: 126-131.
35. Syková E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev 2008; 88: 1277-1340.
36. Thorne RG, Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci USA 2006; 103: 5567-5572.
37. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 2003; 17: 2085-2087.
38. Barranger JA, Rapoport SI, Fredericks WR, Pentchev PG, MacDermot KD, Steusing JK et al. Modification of the blood-brain barrier: increased concentration and fate of enzymes entering the brain. Proc Natl Acad Sci USA 1979; 76: 481-485.
39. Neuwelt EA, Frenkel EP, Rapoport S, Barnett P. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery 1980; 7: 36-43.
40. Siegal T, Rubinstein R, Bokstein F, Schwartz A, Lossos A, Shalom E et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg 2000; 92: 599-605.
41. Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N. The effects of the Na(+)/Ca(+ +) exchange blocker on osmotic blood-brain barrier disruption. Brain Res 2001; 900: 157-162.